Vijay Bhavya, Devkumar Poornima, Saha Gargi, RamachandraRao Satish P
Center for Clinical Research and Education, The University of Trans-Disciplinary Health Sciences and Technology, Bangalore, India.
Center for Clinical Research and Education, The University of Trans-Disciplinary Health Sciences and Technology, Bangalore, India; Internal Medicine - Cardiology, University of Michigan, Ann Arbor, MI, USA.
J Ayurveda Integr Med. 2025 Jan-Feb;16(1):101043. doi: 10.1016/j.jaim.2024.101043. Epub 2025 Jan 28.
Obesity is a rising risk factor for various diseases including cardiovascular diseases and Cancer. The limitations of targeted obesity-treatment approaches employed in the clinic presently underscore the importance of developing integrative management strategies for identification of specific biomarkers of obesity.
Given the specificity of exosome/extracellular vesicle (EV) biomarkers, we aimed here to identify the EV biomarkers of Ayurveda treatment - Lekhana Basti - for Obesity.
A total of eighteen 24-h urine samples from 6 participants with BMI>30 kg/m were used in this study, collected over 3 time-points during the Lekhana basti (medicated enema for obesity) treatment. Urine EV were isolated using Polyethylene Glycol (PEG). The proteins were resolved by 1-d gel electrophoresis and identified using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) and quantified by label-free methods. Significant Protein-Protein Interactions, KEGG pathway analysis and enrichment, functional gene ontology (GO) annotation were identified and shortlisted in comparison to Obesity reference genes from DisGeNET.
With UniProt as a reference subsequent to LC-MS/MS-identification, a total of 210 exosome proteins were identified. Seventy-three proteins were overexpressed in pathway enrichment analysis. Further, GO functional annotation identified 15 common proteins involved. Finally, the 8 hub proteins associated with obesity were identified and their differential expression profile compared between three different time-points during Lekhana Basti treatment. Six protein markers overexpressed during obesity were downregulated post Lekhana Basti treatment, while 2 markers increased in abundance post-treatment.
To our knowledge, this is the first study to isolate and identify urine EV protein abundance profiles from obese female participants of India. The study results indicate significant changes in the differential expression profile of 8 hub proteins involved in obesity, after Lekhana Basti treatment. The biomarker signature of the pilot study indicates the role of Ayurveda treatment and the possible pathways involved in the treatment of Obesity. Further, this study underlines the specificity of urine exosomes/EV as diagnostic markers as well as the potential of Ayurveda treatment in effective management of obesity.
肥胖是包括心血管疾病和癌症在内的各种疾病日益增加的风险因素。目前临床中采用的靶向肥胖治疗方法的局限性凸显了制定综合管理策略以识别肥胖特异性生物标志物的重要性。
鉴于外泌体/细胞外囊泡(EV)生物标志物的特异性,我们旨在识别阿育吠陀疗法——利卡纳灌肠法治疗肥胖的EV生物标志物。
本研究共使用了来自6名体重指数(BMI)>30kg/m²参与者的18份24小时尿液样本,这些样本在利卡纳灌肠法(肥胖症药物灌肠)治疗期间的3个时间点收集。使用聚乙二醇(PEG)分离尿液中的EV。蛋白质通过一维凝胶电泳分离,然后使用液相色谱-串联质谱(LC-MS/MS)进行鉴定,并采用无标记方法进行定量。与来自DisGeNET的肥胖参考基因相比,确定并筛选了显著的蛋白质-蛋白质相互作用、KEGG通路分析和富集、功能基因本体(GO)注释。
在LC-MS/MS鉴定后,以UniProt为参考,共鉴定出210种外泌体蛋白。在通路富集分析中有73种蛋白过表达。此外,GO功能注释鉴定出15种相关的共同蛋白。最后,确定了与肥胖相关的8种枢纽蛋白,并比较了它们在利卡纳灌肠法治疗期间三个不同时间点的差异表达谱。肥胖期间过表达的6种蛋白标志物在利卡纳灌肠法治疗后下调,而2种标志物在治疗后丰度增加。
据我们所知,这是第一项从印度肥胖女性参与者中分离并鉴定尿液EV蛋白丰度谱的研究。研究结果表明,利卡纳灌肠法治疗后,8种参与肥胖的枢纽蛋白的差异表达谱有显著变化。初步研究的生物标志物特征表明了阿育吠陀疗法的作用以及肥胖治疗中可能涉及的途径。此外,本研究强调了尿液外泌体/EV作为诊断标志物的特异性以及阿育吠陀疗法在有效管理肥胖方面的潜力。